

REVIEW ARTICLE

Acute Kidney Injury at the Neurocritical Care Unit



Gonzalo Ramírez-Guerrero^{1,2,3*} , Romyna Baghetti-Hernández^{1,3} and Claudio Ronco^{4,5,6}

© 2021 Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society

Abstract

Neurocritical care has advanced substantially in recent decades, allowing doctors to treat patients with more complicated conditions who require a multidisciplinary approach to achieve better clinical outcomes. In neurocritical patients, nonneurological complications such as acute kidney injury (AKI) are independent predictors of worse clinical outcomes. Different research groups have reported an AKI incidence of 11.6% and an incidence of stage 3 AKI, according to the Kidney Disease: Improving Global Outcomes, that requires dialysis of 3% to 12% in neurocritical patients. These patients tend to be younger, have less comorbidity, and have a different risk profile, given the diagnostic and therapeutic procedures they undergo. Trauma-induced AKI, sepsis, sympathetic overstimulation, tubular epitheliopathy, hyperchloremia, use of nephrotoxic drugs, and renal hypoperfusion are some of the causes of AKI in neurocritical patients. AKI is the result of a sum of events, although the mechanisms underlying many of them remain uncertain; however, two important causes that merit mention are direct alteration of the physiological brain–kidney connection and exposure to injury as a result of the specific medical management and well-established therapies that neurocritical patients are subjected to. This review will focus on AKI in neurocritical care patients. Specifically, it will discuss its epidemiology, causes, associated mechanisms, and relationship to the brain–kidney axis. Additionally, the use and risks of extracorporeal therapies in this group of patients will be reviewed.

Keywords: Acute kidney injury, Critical care, Renal replacement therapy, Traumatic brain injury, Subarachnoid hemorrhage, Cerebral hemorrhage, Stroke, Dialysis

Introduction

Neurocritical care has advanced substantially in recent decades. New neuromonitoring techniques, therapies, and endovascular procedures have emerged [1] to meet the needs of patients with more complicated conditions who require a multidisciplinary approach to achieve better clinical outcomes.

Acute kidney injury (AKI) is a systemic disease that is one of the most frequent and severe complications in patients who are critically ill because of its high morbidity and mortality and economic impact [2, 3]. The increased mortality associated with it is even higher when it is present along with dysfunction of another organ; in this case,

mortality can be as high as 60–80% [4]. This is a frequent scenario; there are reports of additional organ dysfunction apart from central nervous system (CNS) lesions in up to 81% of patients [5].

This review will focus on AKI in neurocritical care patients. Specifically, it will discuss its epidemiology, causes, associated mechanisms, and relationship to the brain–kidney axis. Additionally, the use and risks of extracorporeal therapies in this group of patients will be reviewed.

Epidemiology and Outcomes of AKI in Neurocritical Pathologies

Nonneurological complications in neurocritical patients are known to be independent predictors of worse clinical outcomes [6]. There are few reports on the incidence, prognosis, and risk factors of AKI in

*Correspondence: gonzalo.ramirezg@redsalud.gob.cl

¹ Critical Care Unit, Carlos Van Buren Hospital, Valparaíso, Chile
Full list of author information is available at the end of the article

neurocritical patients or on individual pathologies, such as acute ischemic stroke (AIS) [7], traumatic brain injury (TBI) [8], intracerebral hemorrhage (ICH), or subarachnoid hemorrhage (SAH) [9]. Neurocritical patients tend to be younger, have less comorbidity, and have a different risk profile, given the diagnostic and therapeutic procedures they undergo.

Different research groups have reported an AKI incidence of 11.6% in neurocritical patients in general, with rates that vary according to the specific pathology: an incidence of 9.2% has been reported in patients with TBI [10], 14.5% to 20.9% in patients with AIS, 19% in patients with ICH, and 12% to 23.1% in patients with SAH [9–15] (Table 1). AKI can result in an up to fivefold increase in mortality in direct relation to its severity, lead to poorer functional recovery, and increase the possibility of moderate-to-severe disability at hospital discharge [9, 12, 16, 17]. An incidence of 3% to 12% of stage 3 AKI, according to the Kidney Diseases: Improving Global Outcomes [18], has been reported to require dialysis; this is linked to higher mortality rates (50% to 70%) and severe disability because of a lower possibility of intrahospital rehabilitation in this subgroup of patients [12, 19].

Risk Factors of AKI in Neurocritical Care Unit Patients

Acute kidney injury risk prediction is fundamental for planning diagnostic and therapeutic procedures in neurocritical patients. Multiple specific renal severity scores have been published (Liaño, Bullock, and Chertow, among others) [20], but only one nomogram for neurocritical patients has been reported [21]. An et al.'s [21]

nomogram specified ten risk factors for predicting the occurrence of AKI, with an area under the curve of 0.87. The risk factors included are Glasgow Coma Scale classification; hypertension; coronary disease; pneumonia and heart failure in the first 7 days of hospitalization; and use of furosemide, torsemide, dopamine, and norepinephrine [21]. Covic et al. [11] reported the independent risk factors of AKI of older age, reduced glomerular filtration rate (GFR), and type of AIS. One of the most often reported risk factors for the onset of AKI in neurocritical and nonneurocritical patients is the presence of chronic kidney disease [12].

These severity scores have the limitation of limited external validation, which suggests a poor capacity to discern at-risk patients.

Physiopathology of AKI in Neurocritical Care Unit Patients

The Brain–Kidney Connection

The brain and kidneys share a complex crosstalk to maintain homeostasis. The term crosstalk refers to organ interaction via biological communication through central and peripheral pathways (Fig. 1) [22]. Given this relationship, AKI can generate anatomical, functional, and biochemical changes in the brain, such as changes in the concentration of neurotransmitters and cytokines, acid–base homeostasis, and drug metabolism; this can cause direct and indirect injuries [23]. Concomitantly, efferent impulses from the CNS can increase renal sympathetic activity causing renin secretion, increasing tubular sodium absorption, and decreasing renal blood flow [24].


Table 1 Studies showing incidence of AKI in neurological diseases

Study	Year published	Patients (n)	Diseases	Incidence	Diagnosis criteria
Tsagalis [7]	2009	1,350	Stroke	14.29%	AKIN
Corral [8]	2012	224	TBI	8%	RIFLE
Zacharia [9]	2009	787	SAH	23.1%	RIFLE
Moore [10]	2010	207	TBI	9.2%	RIFLE
Covic [11]	2008	1,090	Stroke	14.5%	RIFLE
Büttner [12]	2020	681	All ^a	11.6%	AKIN
Zorrilla-Vaca [13],b	2017	5,147,754/615,623	Stroke/ICH	12.9%/19%	AKIN
Tujjar [14]	2017	202	SAH	12%	AKIN
Wang [15]	2018	647	Stroke	20.9%	KDIGO
Li [16]	2011	136	TBI	23%	AKIN
Sadan [54]	2017	1,267	SAH	16.7%	KDIGO
Eagles [87]	2019	413	SAH	38%	KDIGO

AKI acute kidney injury, AKIN acute kidney injury network, CNS central nervous system, ICH intracerebral hemorrhage, KDIGO Kidney Disease: Improving Global Outcomes, RIFLE Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease, SAH subarachnoid hemorrhage, TBI traumatic brain injury

^a Neurologic autoimmune disorder, intracranial hemorrhage, infection of the CNS, ischemic stroke, tumor, others

^b Meta-analysis



Inflammation

Experimental evidence from an animal model of AKI has modeled the brain–kidney axis in regard to inflammation. High levels of inflammatory cytokines in the brain and cellular inflammation in astrocytes and microglia, together with anatomic and functional injuries, increased blood–brain barrier (BBB) permeability and pyknosis in neuronal cells [25]. The mechanism that underlies the increase in BBB permeability is not well described. AKI increases proinflammatory cytokines and decreases their clearance, thus increasing the inflammatory response [26]. This suggests that this inflammatory state, as well as other states by entities such as sepsis or liver failure, is a

cause of BBB alteration [27, 28] through facilitation of an influx of water and solutes. Only in AKI models—not in other models of systemic inflammation—has an increase been observed in the cerebral cortex and corpus callosum of keratinocyte-derived chemoattractants and granulocyte colony-stimulating factor, along with specific markers of brain inflammation and extravasation of Evans blue dye in the brain [25]. In animal models, a direct effect of $\text{TNF-}\alpha$ and an indirect effect of the upregulation of matrix metalloproteinase 9 has been demonstrated, which can alter endothelial tight junctions with water and protein extravasation, resulting in vasogenic edema [29, 30]. This is enhanced through aquaporins-4 expression

that is 2.5 times higher than normal, an increase induced by the kidney disease [31].

This inflammatory state is also triggered from the brain to the kidney. Evidence from brain-dead kidney donors has shown greater renal inflammation, with infiltration of T-lymphocytes and macrophages. After perfusing these kidneys, cytokine release was observed, which is a stimulating factor of granulocyte colonies, IL-6, IL-9, and MCP-1 [32].

Neurotransmitter alteration

Neurotransmitter transport is also affected when there is an alteration of BBB permeability. Animal studies have shown that AKI interferes with the Na⁺ independent cationic amino acid transporter (CAT1/SLC7A1), which regulates the influence of L-arginine and thus taurine, alanine, glycine, and creatine. This generates accumulation and/or depletion of amino acids and neurotransmitters in CNS as well as others that are strictly regulated to maintain low concentrations in cerebral tissue, such as glutamate, glycine, and gamma-aminobutyric acid [33].

Metabolic acidosis generated by AKI plays a role in altering neurotransmitter homeostasis and the traffic of neurotransmitters between astrocytes and neurons. Cell acidification increases the oxidative deamination of glutamate through glutamate dehydrogenase, generating an excess of ammonia and, in consequence, altering the cycle of neurotransmitters [27, 34, 35].

Blood flow dysregulation

The brain and kidney have a vascular autoregulation mechanism which maintains blood flow constant despite variations in blood pressure; there is a hemodynamic

parallelism between the vascular beds of both organs to ensure adequate perfusion [36, 37] and close management of sodium correction, fluid tonicity, and water balance [38].

This cerebrovascular and renal regulation is altered in neurocritical patients. It has been observed that sustained cerebral autoregulation in patients with neurocritical pathologies is associated with renal hyperfiltration and that loss of cerebral autoregulation may contribute to an alteration of renal autoregulation, generating a decline in creatinine clearance and increasing susceptibility of developing AKI [39].

Kidney hyperfiltration is a frequent finding in neurocritical care patients and this phenomenon has implications on drug pharmacokinetics [39–41]. Several authors have reported faster elimination of levetiracetam after neurologic injury, with the consequent risk of underdosing for treatment or prophylaxis [42, 43]. The mechanisms that promote increased renal clearance remain poorly understood. Some of those which have been proposed are aggressive fluid resuscitation and vasopressor support, systemic inflammation after trauma, cytokine storm, hypertonic solutions, increased atrial natriuretic peptide and brain–kidney crosstalk in an inflammatory state, and increased sympathetic nervous system activity as common pathways [27, 44–48].

Causes of AKI in neurocritical care unit patients

TBI-induced AKI

Acute kidney injury develops without severe episodes of systemic hypoperfusion and nephrotoxin exposure [49]. The mechanisms proposed in the literature were the following (Table 2):

Table 2 Relevant mechanisms in AKI

AKI in TBI	AKI in SAH	AKI in AIS and ICH
Sepsis-associated AKI	Sepsis-associated AKI	Sepsis-associated AKI
Trauma-related AKI Hemorrhagic shock Rhabdomyolysis Oxidative stress DAMPs/ PAMPs	Induced hydroelectrolytic disorders Hypernatremia Hyperchloremia	Renal hypoperfusion
Sympathetic hyperstimulation Hyperactivity of SNS Activation of HPA axis	Contrast induced AKI	Contrast associated AKI
Tubular epitheliopathy	Osmotic nephrosis	Osmotic nephrosis
Osmotic nephrosis	Drug-induced AIN: Levetiracetam [88–90] Phenytoin [90]	Drug-induced AIN: Levetiracetam [88–90] Phenytoin [90]
Drug-induced AIN: Levetiracetam [88–90] Phenytoin [90]	–	–

AIN acute interstitial nephritis, AIS acute ischemic stroke, AKI acute kidney injury, DAMPs damage-associated molecular patterns, HPA hypothalamic–pituitary–adrenal axis, ICH intracerebral hemorrhage, PAMPs pathogen-associated molecular patterns, SAH subarachnoid hemorrhage, SNS sympathetic nervous system, TBI traumatic brain injury

1. Activation of the brain–kidney axis:
 - a. Sympathetic renal stimulation by sympathetic efferents, which induce the release of noradrenaline and adrenaline by the adrenal gland. Catecholamines stimulate beta 1 adrenergic receptors, increasing renin secretion by the juxtaglomerular cells, which increases Na^+ and water reabsorption in addition to producing a vasopressor effect. Catecholamines also stimulate alpha 1 adrenergic receptors in the kidney vasculature, decreasing renal blood flow, GFR, and urine output [50].
 - b. Activation of the hypothalamic–pituitary–adrenal axis as a direct trauma-induced result that increases endogenous catecholamines [50].
2. Functional alterations and apoptosis of renal tubular epithelial cells secondary to a systemic inflammatory reaction in severe brain injury:
 - a. Increased proteinuria and plasma neutrophil gelatinase-associated lipocalin (NGAL) have been shown in one in vitro study. These markers of tubular damage correlated with inflammatory mediators, suggesting that acute brain damage generates tubular injury. The cellular mechanism proposed is based on the inflammatory mediators such as IL-6, MCP-1, and MIP1 beta contained in the plasma of patients with TBI, which are involved in neutrophil adhesion to tubular epithelial cells. This injures the epithelium through the disassembly of tight junctions and the degradation of elastases and matrix metalloproteinases [49].
3. Autonomic nervous system dysregulation:
 - a. An imbalance in the parasympathetic and sympathetic pathway in patients with severe TBI results in hyperactivity of the sympathetic nervous system, causing a hyperadrenergic state or paroxysmal sympathetic hyperactivity, as this clinical condition is known. Any anatomical injury to areas that control the autonomic nervous system can result in autonomic dysregulation (hypothalamus, nucleus of the solitary tract, areas A1 to A5 of the medulla, and subfornical organ) and the increased sympathetic tone results in renal vasoconstriction and decreased renal perfusion [51].

AKI in Subarachnoid Hemorrhage

In contrast to TBI-induced AKI, SAH is not an early complication. Most episodes occur >1 week after

intensive care unit admission [14] because of intensive care unit-specific interventions and medical management strategies, such as use of hyperosmolar therapy and potential exposure to nephrotoxic agents such as intravenous contrast media [52] (Table 2). The mechanisms are the following:

1. Hyponatremia and hyperchloremia due to use of hypertonic saline therapy:
 - a. Hypertonic saline therapy is often used to control intracranial hypertension and hyponatremia. Hyponatremia and hyperchloremia produce intravascular dehydration and vasoconstriction either directly or through tubuloglomerular feedback mechanisms [52]. A randomized trial comparing a low-chloride (NaCl/Na-acetate) versus high-chloride hypertonic solution (NaCl) for patients who required hyperosmolar therapy for SAH revealed that the rate of AKI was higher in the NaCl group (53.3% vs. 11.8%, $p=0.01$) and suggested that patients with a chloride level of 109 mmol/L or above are those at highest risk for AKI [53, 54].
2. Contrast-induced AKI:
 - a. The patient population with SAH has an increased risk of contrast-induced nephropathy through multiple exposures to IV contrast media secondary to the diagnosis and treatment of intracranial aneurysm, such as computed tomography angiography and coil embolization [55].

AKI in AIS and Intracerebral Hemorrhage

The mechanisms were the following:

1. Intensive reduction of systolic blood pressure in ICH:
 - a. As recommended by current guidelines, an acute reduction of systolic blood pressure to 140 mm Hg can improve functional outcomes in patients with ICH [56], but it is strongly associated with AKI [57].
2. Contrast-associated AKI in endovascular thrombectomy in AIS:
 - a. Additional exposure to contrast media in addition to what is received during diagnostic imaging techniques along with use of intraarterial contrast increase the risk of contrast-associated AKI more than intravenous contrast media. It occurs in 1 out of 30 patients [58].
3. Infusion rate of mannitol used to decrease intracranial pressure in patients with ICH:

-
- a. Mannitol accumulation in the extracellular space causes an increase in local renal osmolality and osmotic nephrosis, renal vasoconstriction, and deterioration of the GFR [59].

Renal Replacement Therapy in Neurocritical Care

Despite the undisputed benefit of renal replacement therapy (RRT) in encephalopathy due to retention of nitrogen products and toxic drugs, metabolic acidosis, and sodium and water balance, these therapies may pose a risk to neurocritical patients. They may cause dialysis-associated neurovascular injury and affect the treatment prescribed by the rest of the neurocritical unit team, regardless of the type of therapy used.

Intermittent and continuous therapies have been found to be equally effective regarding mortality and/or dialysis dependence, but reports have shown significant differences in neurocritical patients [60]. The mechanism and speed at which blood purification occurs is the major difference between the two types of therapies: the goal of removal uremic solutes through diffusion is achieved in a short period of time in the case of intermittent therapies [61].

This scenario affects the brain–kidney connection because of an effective therapy. The neurological consequences include de novo cerebral edema or an increase of existing edema, herniation, neurological impairment, or death; thus, neurocritical patients merit special consideration when planning RRT [62]. Our therapeutic goals must be to prevent secondary damage by maintaining proper cerebral blood flow (CBF) and cerebral perfusion pressure (CPP) together with intracranial pressure (ICP) control, which may be significantly affected by these therapies, with their consequent prognostic implications [63]. Continuous RRT (CRRT) has proven to be associated with better mean blood pressure, cardiac output, and oxygen delivery outcomes compared with intermittent hemodialysis (IHD). It offers a better hemodynamic profile and, therefore, better CPP and CBF control, which leads it to be associated with better neurological outcomes [63, 64].

Significant changes in the density of white and gray matter have been observed after an IHD session in all patients with increased water content in the brain, but these changes were not observed after CRRT [65]. In addition, IHD has also been shown to lead to decreased circulating blood volume and decreased CBF, as has been demonstrated by transcranial Doppler imaging. Furthermore, the absolute brain tissue oxygen tension level was lower during IHD [66, 67] and hypotension was more frequently reported as a complication of IHD compared to CRRT [68]. Possible mechanisms that

could explain this are increased oxygen consumption secondary to ICP surges (associated with brain hypermetabolism and increased oxygen consumption) and limited brain oxygen diffusion due to increased brain water content [69].

One of the problems with IHD that is associated with the rapid removal of urea, sodium, and other osmoles from the vascular compartment is the compartmentalization of these osmoles at the intracranial level. As this area has a slower removal rate, an osmolar gradient is generated between the two compartments, which triggers the diffusion of water into the brain and a significant increase in ICP during treatment [70, 71]. This phenomenon of dialysis disequilibrium syndrome and cerebral vasogenic edema [72] can be explained through different mechanisms. First, the reverse urea effect occurs, which is slower removal of urea from cerebrospinal fluid than from the blood during IHD, causing the aforementioned gradient. This is subsequently supported by findings of urea transporters, which are downregulated in uremic states, causing a reduced adaptive response in the brain to rapid changes in plasma urea and accentuated by overregulation of aquaporin channels, increasing water entry into the brain regardless of the degree of urea reduction [31, 70, 73, 74]. The second mechanism underlying dialysis disequilibrium syndrome is the hypothesis of idiogenic osmoles, in which osmotically active molecules (not including urea, Na^+ , K^+ , or Cl^-) contribute to cerebral edema [75]. The third mechanism is the hypothesis of paradoxical CNS acidosis, in which the decreased brain pH produced by the correction of systemic acidosis through RRT with elevated bicarbonate concentrations in the dialysate generates an osmotic gradient through the release of intracellular protein-bound sodium and potassium. This mechanism is accentuated by a reduction in CPP caused by the therapy, causing cerebral hypoxia and cerebral acidosis with the production of local vasodilators, increasing vasogenic edema [76, 77].

Unlike CRRT, IHD treatments can worsen the clinical conditions of patients with cerebral edema because of a postdialytic influx of fluid into the brain (Fig. 2) [78]. Therefore, CRRT should be the first option in these patients (Table 3). Moreover, it has been suggested that citrate may provide neuroprotection by attenuating hypoxic brain injury through its effects on astrocytes and oxidative phosphorylation [79].

Nevertheless, if only IHD is available, the initial decline in osmolality should be moderated by slower dialysate and blood flows coupled with a smaller dialyzer surface, a high dialysate sodium content, and daily treatment to reduce changes in serum urea [80]. These factors must be taken into account independently of the type of




Table 3 Central nervous system effects of CRRT versus IHD

IHD	CRRT
Decreased circulatory blood volume	Prefixed sodium
Decreased CBF	Hypophosphatemia induced hypoxia due to high affinity
Decreased PbtO ₂	Anticoagulation
Increased ICP	–
Cerebral vasodilation	–
Changes in density of white and gray matter	–
DDS/DANI	–

CBF cerebral blood flow, CRRT continuous renal replacement therapy, DANI dialysis-associated neurovascular injury, DDS dialysis disequilibrium syndrome, ICP intracranial pressure, IHD intermittent hemodialysis, PbtO₂ brain tissue oxygenation

technique used and the patient’s plasma osmolality and sodium and blood urea nitrogen (BUN) levels should be routinely monitored.

Natremia and CRRT

A controlled correction of natremia or maintaining a target natremia is essential when prescribing CRRT, given that despite the safety elements mentioned above regarding IHD, cases of significant reductions in osmolality—up to 35 mOsm/kg within the first 24 h of starting CRRT—have been observed [81]. A problem with CRRT replacement solutions is that the sodium in them is prefixed, ranging from 136 to 140 mmol/L. Therefore,

this must be managed through the dialysate/replenished fluid in order to achieve the desired goal. Practical algorithms, such as those reported by Dangoisse et al. [82], or formulas according to the sodium kinetic model can be used. The must be modified for a single-pool, fixed-volume equation to quantify the changes of natremia during CRRT.

$$Na_{(t)} = Na_0 + (Na_{dial/RF} - Na_0) \times (1 - e^{-Dt/V}) \quad (1)$$

where $Na_{dial/RF}$ is the sodium concentration in the solutions; Na_0 is the patient’s initial sodium level; D is the effective sodium dialysance, which is almost the same as effective urea clearance; t is the time from the beginning of CRRT; and V is the total volume of body water, estimated via the Watson formula and with estimated edema volume added on [83].

Hypophosphatemia and RRT

Another key factor to consider during CRRT is the presence of hypophosphatemia, which has been reported in around 80% of patients who undergo these procedures [84]. Hypophosphatemia produces a decrease in 2,3-diphosphoglycerate in erythrocytes, increasing the affinity of hemoglobin for oxygen and causing a reduction in intracellular adenosine triphosphate [85]. This disorder caused by CRRT can alter the multimodal monitoring values in the case of brain tissue oxygen tension by causing hypoxia due to high affinity. Therefore, when it is present, supplementation with 1.2 to 2 mmol/L of

phosphorus in the replenishment/dialysis solutions is an option [86].

Regardless of the cause that leads to starting RRT, nephrologists must be extremely cautious with findings that suggest edema, dialysate composition, and changes in plasma osmolality. They must consider not only sodium and BUN but also the goals set by the neurocritical care team so as not to hinder them with interventions aimed at improving renal outcomes.

Conclusions

Acute kidney injury is a frequent complication in neurocritical patients that involves different pathologies, such as TBI, SAH, and stroke. Its presence in these patients is associated with worse clinical outcomes that directly affects morbidity, mortality, and functional dependence.

AKI in neurocritical patients is the result of a sum of events, although the mechanisms that underlie most of them remain uncertain. However, it is important to highlight the direct alteration of the physiological brain–kidney connection and exposure to injury as result of the specific medical management and well-established therapies these patients undergo.

Each neurocritical pathology has a specific risk for the development of AKI. Knowledge of these risks is necessary to minimize their incidence in our daily clinical practice. Furthermore, it is important to know the complications associated with RRT in this group of patients to prevent them while still maintaining our therapeutic objectives.

Source of Support

There was no funding for the study.

Author details

¹ Critical Care Unit, Carlos Van Buren Hospital, Valparaíso, Chile. ² Dialysis and Renal Transplant Unit, Carlos Van Buren Hospital, Valparaíso, Chile. ³ Department of Medicine, Universidad de Valparaíso, Valparaíso, Chile. ⁴ Department of Medicine, Università di Padova, Padua, Italy. ⁵ Department of Nephrology, Dialysis and Kidney Transplantation, San Bortolo Hospital, Vicenza, Italy. ⁶ International Renal Research Institute of Vicenza, Vicenza, Italy.

Acknowledgements

The authors thank Anita Zurita Poza for her excellent technical assistance. GRG thanks Biorender for the design of the figures.

Author Contributions

GRG, RBH designed the work, GRG, RBH collected and analyzed the data, GRG, RBH, and CR drafted the work or substantively revised it, and all authors read and approved the final manuscript.

Declarations

Conflict of interest

The authors report no conflicts of interest. The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this article. The authors alone are responsible for the content and writing of this article.

Ethical Approval/Informed Consent

Not applicable.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 30 June 2021 Accepted: 30 August 2021

Published online: 13 September 2021

References

1. Van der Schaaf I, Algra A, Wemer M, et al. Endovascular coiling versus neurosurgical clipping for patients with aneurysmal subarachnoid haemorrhage. *Cochrane Database Syst Rev.* 2005;19(4):CD003085.
2. Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. *J Am Soc Nephrol.* 2005;16:3365–70.
3. Uchino S, Kellum JA, Bellomo R, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA.* 2005;294:813–8.
4. Chertow GM, Christiansen CL, Cleary PD, et al. Prognostic stratification in critically ill patients with acute renal failure requiring dialysis. *Arch Intern Med.* 1995;155:1505–11.
5. Gruber A, Reinprecht A, Illievich UM, et al. Extracerebral organ dysfunction and neurologic outcome after aneurysmal subarachnoid hemorrhage. *Crit Care Med.* 1999;27:505–14.
6. Zygun D. Non-neurological organ dysfunction in neurocritical care: impact on outcome and etiological considerations. *Curr Opin Crit Care.* 2005;11(2):139–43.
7. Tsagalis G. Renal dysfunction in acute stroke: an independent predictor of long-term all combined vascular events and overall mortality. *Nephrol Dial Transplant.* 2009;24(1):194–200.
8. Corral L. Impact of non-neurological complications in severe traumatic brain injury outcome. *Crit Care.* 2012;16(2):R44.
9. Zacharia BE. Renal dysfunction as an independent predictor of outcome after aneurysmal subarachnoid hemorrhage: a single-center cohort study. *Stroke.* 2009;40(7):2375–81.
10. Moore EM, Bellomo R, Nichol A, Harley N, Macisaac C, Cooper DJ. The incidence of acute kidney injury in patients with traumatic brain injury. *Ren Fail.* 2010;32(9):1060–5.
11. Covic A, Schiller A, Mardare NG, et al. The impact of acute kidney injury on short-term survival in an Eastern European population with stroke. *Nephrol Dial Transplant.* 2008;23(7):2228–34.
12. Buttner S, Stadler A, Mayer C, et al. Incidence, risk factors, and outcome of acute kidney injury in neurocritical care. *J Intensive Care Med.* 2020;35(4):338–46.
13. Zorrilla-Vaca A, Ziai W, Sander E, Geocadin R, Thompson R, Rivera-lara L. Acute kidney injury following acute ischemic stroke and intracerebral hemorrhage: A meta-analysis of prevalence rate and mortality risk. *Cerebrovasc Dis.* 2017;45:1–9.
14. Tujjar O, Belloni I, Hougardy JM, et al. Acute kidney injury after subarachnoid hemorrhage. *J Neurosurg Anesthesiol.* 2017;29(2):140–9.
15. Wang D, Guo Y, Zhang Y, Li Z, Li A, Luo Y. Epidemiology of acute kidney injury in patients with stroke: a retrospective analysis from the neurology ICU. *Intern Emerg Med.* 2018;13(1):17–25.
16. Li N, Zhao WG, Zhang WF. Acute kidney injury in patients with severe traumatic brain injury: implementation of the acute kidney injury network stage system. *Neurocrit Care.* 2011;14:377–81.
17. Saeed F, Adil MM, Khursheed F, et al. Acute renal failure is associated with higher death and disability in patients with acute ischemic stroke: analysis of nationwide inpatient sample. *Stroke.* 2014;45:1478–80.

18. Kidney Disease: Improving Global Outcomes (KDIGO) Acute kidney Injury Work Group. KDIGO Clinical Practice Guideline for Acute Kidney Injury. *Kidney Int Suppl.* 2012;2:1–138
19. Nadkarni G, Patel A, Konstantinidis I, et al. Dialysis requiring acute kidney injury in acute cerebrovascular accident hospitalizations. *Stroke.* 2015;46(11):3226–31.
20. Shigehiko U, Chapter 6 – Kidney-Specific Severity Score, Editor(s): Claudio Ronco, Rinaldo Bellomo, John A. Kellum, Zaccaria Ricci, *Critical Care Nephrology (Third Edition)*, Elsevier, 2019, 29–34. E1. ISBN 9780323449427.
21. An S, Luo H, Wang J, et al. An acute kidney injury prediction nomogram based on neurosurgical intensive care unit profiles. *Ann Transl Med.* 2020;8(5):194.
22. Zhao Q, Yan T, Chopp M, Venkat P, Chen J. Brain-kidney interaction: Renal dysfunction following ischemic stroke. *J Cereb Blood Flow Metab.* 2020;40(2):246–62.
23. Palkovits M, Sebekova K, Gallatz K, et al. Neuronal activation in the CNS during different forms of acute renal failure in rats. *Neuroscience.* 2009;159:862–82.
24. DiBona GF. Physiology in perspective: the Wisdom of the Body. Neural control of the kidney. *Am J Physiol Regul Integr Comp Physiol.* 2005;289:R633–41.
25. Liu M, Liang Y, Chigurupati S, et al. Acute kidney injury leads to inflammation and functional changes in the brain. *J Am Soc Nephrol.* 2008;19(7):1360–70.
26. Andres-Hernando A, Dursun B, Altmann C, et al. Cytokine production increases and cytokine clearance decreases in mice with bilateral nephrectomy. *Nephrol Dial Transpl.* 2012;27:4339–47.
27. Nongunch A, Panorchan K, Davenport A. Brain-kidney crosstalk. *Crit Care.* 2014;18:225.
28. Lu R, Kiernan MC, Murray A, Rosner MH, Ronco C. Kidney-brain crosstalk in the acute and chronic setting. *Nat Rev Nephrol.* 2015;11(12):707–19.
29. Tsao N, Hsu HP, Wu CM, Liu CC, Lei HY. Tumor necrosis factor-alpha causes an increase in blood-brain barrier permeability during sepsis. *J Med Microbiol.* 2001;50:812–21.
30. Wiggins-Dohlvik K, Merriman M, Shaji CA, et al. Tumor necrosis factor-alpha disruption of brain endothelial cell barrier is mediated through matrix metalloproteinase-9. *Am J Surg.* 2014;208:954–60.
31. Trinh-Trang-Tan MM, Cartron JP, Bankir L. Molecular basis for the dialysis disequilibrium syndrome: altered aquaporin and urea transporter expression in the brain. *Nephrol Dial.* 2005;20:1984–8.
32. de Vries DK, Lindeman JH, Ringers J, et al. Donor brain death predisposes human kidney grafts to a proinflammatory reaction after transplantation. *Am J Transplant.* 2011;11:1064–70.
33. O’Kane RL, Vina JR, Simpson I, Zaragoza R, Mokashi A, Hawkins RA. Cationic amino acid transport across the blood-brain barrier is mediated exclusively by system y+. *Am J Physiol Endocrinol Metab.* 2006;291:412–9.
34. Zaganas I, Pajacka K, Wender C, Schousboe A, Waagepetersen HS, Plaitakis A. The effect of pH and ADP on ammonia affinity for human glutamate dehydrogenases. *Metab Brain Dis.* 2013;28(2):127–31.
35. Rothman D, De Feyter HM, Maciejewski PK, Behar KL. Is there in vivo evidence for amino acid shuttles carrying ammonia from neurons to astrocytes? *Neurochem Res.* 2012;37(11):2597–612.
36. Lassen NA. Autoregulation of cerebral blood flow. *Circ Res.* 1964;15(suppl):201–4.
37. Just A. Mechanisms of renal blood flow autoregulation: dynamics and contributions. *Am J Physiol Regul Integr Comp Physiol.* 2007;292:R1–17.
38. Davenport A. The brain and the kidney-organ cross talk and interactions. *Blood Purif.* 2008;26:526–36.
39. Dias C, Gaio R, Monteiro E, et al. Kidney-Brain link in traumatic brain injury patients? A preliminary report *Neurocrit Care.* 2015;22(2):192–201.
40. Udy A, Boots R, Senthuran S, et al. Augmented creatinine clearance in traumatic brain injury. *Anesth Analg.* 2010;111:1505–10.
41. Minville V, Asehnoune K, Ruiz S, et al. Increased creatinine clearance in polytrauma patients with normal serum creatinine: a retrospective observational study. *Crit Care.* 2011;15:R49.
42. Spencer DD, Jacobi J, Juenke JM, Fleck JD, Kays MB. Steady-state pharmacokinetics of intravenous levetiracetam in neurocritical care patients. *Pharmacotherapy.* 2011;31:934–41.
43. Drust A, Luchtmann M, Firsching R, Tröger U, Martens-Lobenhoffer J, Bode-Böger SM. Recurrent seizures in a levetiracetam-treated patient after subarachnoid hemorrhage: a matter of enhanced renal function? *Epilepsy Behav.* 2012;23(3):394–5.
44. Wan L, Bellomo R, May CN. A comparison of 4% succinylated gelatin solution versus normal saline in stable normovolaemic sheep: global haemodynamic, regional blood flow and oxygen delivery effects. *Anaesth Intensive Care.* 2007;35:924–31.
45. Di Giantomaso D, May CN, Bellomo R. Norepinephrine and vital organs blood flow during experimental hyperdynamic sepsis. *Intensive Care Med.* 2003;29:1774–81.
46. Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. *Injury.* 2007;38:1336–45.
47. Ott L, McClain CJ, Gillespie M, Young B. Cytokines and metabolic dysfunction after severe head injury. *J Neurotrauma.* 1994;11:447–72.
48. Udy AA, Jarrett P, Lassig Smith M, Suart J, Starr T, Dunlop R, et al. Augmented renal clearance in traumatic brain injury: a single-center observational study of atrial natriuretic peptide, cardiac output, and creatinine clearance. *J Neurotrauma.* 2017;34:137–44.
49. Civiletti F, Assenzio B, Mazzeo AT, et al. Acute tubular Injury is Associated With severe traumatic Brain Injury: in Vitro study on Human tubular epithelial Cells. *Sci Rep.* 2019;9(1):6090.
50. Messerer DAC, Halbgebauer R, Nilsson B, Pavenstädt H, Radermacher P, Huber-Lang M. Immunopathophysiology of trauma-related acute kidney injury. *Nat Rev Nephrol.* 2021;17(2):91–111.
51. Khalid F, Yang GL, McGuire JL, et al. Autonomic dysfunction following traumatic brain injury: translational insights. *Neurosurg Focus.* 2019;47(5):E8.
52. Kumar AB, Shi Y, Shotwell MS, Richards J, Ehrenfeld JM. Hypernatremia is a significant risk factor for acute kidney injury after subarachnoid hemorrhage: a retrospective analysis. *Neurocrit Care.* 2015;22(2):184–91.
53. Sadan O, Singbartl K, Kraft J, et al. Low-chloride-versus high-chloride-containing hypertonic solution for the treatment of subarachnoid hemorrhage-related complications: The ACETaE (A low ChloriE hyperTonic solution for brain Edema) randomized trial. *J Intensive Care.* 2020;4(8):32.
54. Sadan O, Singbartl K, Kandiah PA, Martin KS, Samuels OB. Hyperchloremia is associated with acute kidney injury in patients with subarachnoid hemorrhage. *Crit Care Med.* 2017;45(8):1382–8.
55. Lee HG, Kim WK, Yeon JY. Contrast-Induced Acute Kidney Injury after Coil Embolization for Aneurysmal Subarachnoid Hemorrhage. *Yonsei Med J.* 2018;59(1):107–12.
56. Hemphill JC 3rd, Greenberg SM, Anderson CS, et al.; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2015;46:2032–60.
57. Qureshi AI, Palesch YY, Martin R, et al; Antihypertensive Treatment of Acute Cerebral Hemorrhage Investigators. Systolic blood pressure reduction and risk of acute renal injury in patients with intracerebral hemorrhage. *Am J Med* 2012;125(7):718.e1–6.
58. Diprose WK, Sutherland LJ, Wang MTM, Barber PA. Contrast-associated acute kidney injury in endovascular thrombectomy patients with and without baseline renal impairment. *Stroke.* 2019;50(12):3527–31.
59. Kim MY, Park JH, Kang NR, et al. Increased risk of acute kidney injury associated with higher infusion rate of mannitol in patients with intracranial hemorrhage. *J Neurosurg.* 2014;120(6):1340–8.
60. Ghahramani N, Shadrou S, Hollenbeak C. A systematic review of continuous renal replacement therapy and intermittent haemodialysis in management of patients with acute renal failure. *Nephrology.* 2008;13:570–8.
61. Patel P, Nandwani V, McCarthy P, Conrad S, Scott LK. Continuous renal replacement therapies: A brief primer for the neurointensivist. *Neurocrit Care.* 2010;13:286–94.
62. Osgood M, Compton R, Carandang R, Hall W, Kershaw G, Muehlschlegel S. Rapid unexpected brain herniation in association with renal replacement therapy in acute brain injury: caution in the neurocritical care unit. *Neurocrit Care.* 2015;22:176–83.
63. Donnelly J, Budohoski KP, Smielewski P, Czosnyka M. Regulation of the cerebral circulation: bedside assessment and clinical implications. *Crit Care.* 2016;20(1):129.

-
64. Davenport A, Will EJ, Davidson AM. Improved cardiovascular stability during continuous modes of renal replacement therapy in critically ill patients with acute hepatic and renal failure. *Crit Care Med*. 1993;21(2):328–38.
 65. Ronco C, Bellomo R, Brendolan A, Pinna V, La Greca G. Brain density changes during renal replacement in critically ill patients with acute renal failure. Continuous hemofiltration versus intermittent hemodialysis. *J Nephrol*. 1999;12(3):173–8.
 66. Hata R, Matsumoto M, Handa N, Terakawa H, Sugitani Y, Kamada T. Effects of hemodialysis on cerebral circulation evaluated by transcranial Doppler ultrasonography. *Stroke*. 1994;25:408–12.
 67. Ko S, Choi HA, Gilmore E, Schmidt JM, Claassen J, Lee K. Pearls & Oy-sters: The effects of renal replacement therapy on cerebral autoregulation. *Neurology*. 2012;78(6):e36–8.
 68. Uchino S, Bellomo R, Kellum JA. Patients and kidney survival by dialysis modality in critically ill patients with acute kidney injury. *Int J Artif Organs*. 2007;30(4):281–92.
 69. Bucci MN, Dechert RE, Arnoldi DK, Campbell J, McGillicyduddu JE, Bartlett RH. Elevated intracranial pressure associated with hypermetabolism in isolated head trauma. *Acta Neurochir (Wien)*. 1988;93(3–4):133–6.
 70. Kennedy AC, Linton AL, Luke RG, Renfrew S, Dinwoodie A. The pathogenesis and prevention of cerebral dysfunction during dialysis. *Lancet*. 1964;1(7337):790–3.
 71. Bertrand YM, Hermant A, Mahieu P, Roeb J. Intracranial pressure changes in patients with head trauma during hemodialysis. *Intensive Care Med*. 1983;9:321–3.
 72. Chen CL, Lai PH, Chou KJ, Lee PT, Chung HM, Fang HC. A preliminary report of brain edema in patients with uremia at first hemodialysis: evaluation by diffusion-weighted MR imaging. *AJNR Am J Neuroradiol*. 2007;28:68–71.
 73. Silver SM, DeSimone JA Jr, Smith DA, Sterns RH. Dialysis disequilibrium syndrome (DDS) in the rat: role of the “reverse urea effect.” *Kidney Int*. 1992;42:161–6.
 74. Hu MC, Bankir L, Michelet S, Rousselet G, Trinh-Trang-Tan MM. Massive reduction of urea transporters in remnant kidney and brain of uremic rats. *Kidney Int*. 2000;58:1202–10.
 75. Arieff AI, Massry SG, Barrientos A, Kleeman CR. Brain water and electrolyte metabolism in uremia: effects of slow and rapid hemodialysis. *Kidney Int*. 1973;4:177–87.
 76. Arieff AI, Guisado R, Massry SG, Lazarowitz VC. Central nervous system pH in uremia and the effects of hemodialysis. *J Clin Invest*. 1976;58:306–11.
 77. Hamdi T. Pathogenesis of cerebral edema in patients with acute renal and liver failure and the role of the nephrologist in the management. *Curr Opin Nephrol Hypertens*. 2018;27(4):289–97.
 78. Ronco C. Continuous dialysis is superior to intermittent dialysis in acute kidney injury of the critically ill patients. *Nat Clin Pract Nephrol*. 2007;3(3):118–9.
 79. Keller JA, Chan TY, Chan PH, Gregory GA. Protection of astrocytes by fructose 1,6 bisphosphate and citrate ameliorates neuronal injury under hypoxic conditions. *Brain Res*. 1996;726:167–73.
 80. Davenport A. Management of acute kidney injury in neurotrauma. *Hemodial Int*. 2010;14(1):S27–31.
 81. Liotta EM, Bauer RM, Berman MD, et al. Acute changes in ventricular volume during treatment for hepatic and renal failure. *Neurol Clin Pract*. 2014;4:478–81.
 82. Dangoisse C, Dickie H, Tovey L, Ostermann M. Correction of hyper- and hyponatraemia during continuous renal replacement therapy. *Nephron Clin Pract*. 2014;128:394–8.
 83. Pozzoni P, Di Filippo S, Pontoriero G, Locatelli F. Effectiveness of sodium and conductivity kinetic models in predicting end-dialysis plasma water sodium concentration: preliminary results of a single-center experience. *Hemodialysis Int*. 2007;11(2):169–77.
 84. Broman M, Carlsson O, Friberg H, Wieslander A, Godaly G. Phosphate-containing dialysis solution prevents hypophosphatemia during continuous renal replacement therapy. *Acta Anaesthesiol Scand*. 2011;55(1):39–45.
 85. Massry SG, Fadda GZ, Perna AF, Kierszstein M, Smogorzewski M. Mechanism of organ dysfunction in phosphate depletion: a critical role for a rise in cytosolic calcium. *Miner Electrolyte Metab*. 1992;18:133–40.
 86. Troyanov S, Geadah D, Ghannoum M, et al. Phosphate addition to hemodiafiltration solution during continuous renal replacement therapy. *Intensive Care Med*. 2004;30:1662–5.
 87. Eagles M, Powell MF, Ayling OGS, Tso MK, Macdonald RL. Acute kidney injury after aneurysmal subarachnoid hemorrhage and its effect on patient outcome: an exploratory analysis. *J Neurosurg*. 2019;12(12):1–8.
 88. Chau K, Yong J, Ismail K, Griffith N, Liu M, Makris A. Levetiracetam-induced severe acute granulomatous interstitial nephritis. *Clin Kidney J*. 2012;5:234–6.
 89. Hurwitz KA, Ingulli EG, Krous HF. Levetiracetam induced interstitial nephritis and renal failure. *Pediatr Neurol*. 2009;41:57–8.
 90. Rossert J. Drug-induced acute interstitial nephritis. *Kidney Int*. 2001;60(2):804–17.